International guidelines for the treatment of Huntington's Disease

Bachoud-Levi, Anne-Catherine, Ferreira, Joaquim, Massart, Renaud, Youssov, Katia, Rosser, Anne ORCID: https://orcid.org/0000-0002-4716-4753, Busse-Morris, Monica ORCID: https://orcid.org/0000-0002-5331-5909, Craufurd, David, Reilmann, Ralf, Michele, Giuseppe De, Rae, Daniela, Squitieri, Ferdinando, Seppi, Klaus, Perrine, Charles, Scherer-Gagou, Clarisse, Audrey, Olivier, Verny, Christophe and Burgunder, Jean-Marc 2019. International guidelines for the treatment of Huntington's Disease. Frontiers in Neurology 10 , 710. 10.3389/fneur.2019.00710

	Microsoft Excel (XLSX) (Appendix 1) - Supplemental Material Download (27kB)
Preview	PDF (Appendix 2) - Supplemental Material Download (566kB) | Preview
Preview	PDF - Published Version Available under License Creative Commons Attribution. Download (531kB) | Preview

Abstract

The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). The objectives of such guidelines are to standardize pharmacological, surgical and non-pharmacological treatment regimen and improve care and quality of life of patients. A formalized consensus method, adapted from the French Health Authority recommendations was used. First, national committees (French and English Experts) reviewed all studies published between 1965 and 2015 included dealing with HD symptoms classified in motor, cognitive, psychiatric, and somatic categories. Quality grades were attributed to these studies based on levels of scientific evidence. Provisional recommendations were formulated based on the strength and the accumulation of scientific evidence available. When evidence was not available, recommendations were framed based on professional agreement. A European Steering committee supervised the writing of the final recommendations through a consensus process involving two rounds of online questionnaire completion with international multidisciplinary HD health professionals. Patients' associations were invited to review the guidelines including the HD symptoms. Two hundred and nineteen statements were retained in the final guidelines. We suggest to use this adapted method associating evidence base–medicine and expert consensus to other rare diseases.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences Centre for Trials Research (CNTRR) Medicine
Publisher:	Frontiers
ISSN:	1664-2295
Date of First Compliant Deposit:	24 June 2019
Date of Acceptance:	17 June 2019
Last Modified:	09 Oct 2023 06:54
URI:	https://orca.cardiff.ac.uk/id/eprint/123693

Citation Data

Cited 52 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item